Company profile
Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Elacestrant | phase1_2 | — | 2 | terminated, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06515613 | phase1 | recruiting | 2024-07-10 | 2028-05-31 | Context Therapeutics Inc. | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors |
| NCT07545122 | phase1 | recruiting | 2026-09-01 | 2030-01-01 | Context Therapeutics Inc. | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers |
| NCT06938711 | phase1_2 | withdrawn | 2023-06-01 | 2023-11-01 | Context Therapeutics Inc. | A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer |
| NCT06756035 | phase1 | recruiting | 2025-03-31 | 2026-12-01 | Context Therapeutics Inc. | CT-95 in Advanced Cancers Associated With Mesothelin Expression |
| NCT05618613 | phase1_2 | terminated | 2022-12-02 | 2023-06-23 | Context Therapeutics Inc. | Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer |
FDA applications (0)
No records yet.